Skip to main content
. 2024 May 28;15:1366035. doi: 10.3389/fphar.2024.1366035

FIGURE 8.

FIGURE 8

Risks of adverse drug reactions, including renal insufficiency (A), hyperkalemia (B), and symptomatic hypotension (C) with sacubitril–valsartan vs. ACEI/ARB in AMI patients after PPCI. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.